Home » Stocks » Bluebird Bio

Bluebird Bio, Inc. (BLUE)

Stock Price: $62.49 USD -3.28 (-4.99%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $64.49 +2.00 (3.20%) Aug 11, 5:58 PM

Stock Price Chart

Key Info

Market Cap 4.14B
Revenue (ttm) 239.66M
Net Income (ttm) -653.46M
Shares Out 66.22M
EPS (ttm) -11.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $62.49
Previous Close $65.77
Change ($) -3.28
Change (%) -4.99%
Day's Open 65.99
Day's Range 62.30 - 66.06
Day's Volume 600,837
52-Week Range 38.95 - 126.39

More Stats

Market Cap 4.14B
Enterprise Value 2.78B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 66.22M
Float 65.90M
EPS (basic) -11.77
EPS (diluted) -11.53
FCF / Share -8.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.35M
Short Ratio 6.28
Short % of Float 19.97%
Beta 2.31
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 17.27
PB Ratio 2.59
Revenue 239.66M
Operating Income -672.85M
Net Income -653.46M
Free Cash Flow -487.32M
Net Cash 1.35B
Net Cash / Share 20.44
Gross Margin -225.62%
Operating Margin -280.75%
Profit Margin -272.70%
FCF Margin -203.34%
ROA -20.36%
ROE -39.38%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (22)

Buy 16
Overweight 1
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$105.33*
(68.55% upside)
Low
68.0
Current: $62.49
High
196.0
Target: 105.33
*Average 12-month price target from 18 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue44.6754.5835.436.1614.0825.4220.180.340.88
Revenue Growth-18.15%54.06%475.58%-56.28%-44.62%25.97%5835.59%-61.45%-
Gross Profit41.7053.6933.906.1614.0825.4220.180.340.88
Operating Income-812-569-333-264-166-60.38-24.95-23.72-15.14
Net Income-790-556-336-264-167-48.71-25.32-23.67-15.60
Shares Outstanding55.1952.0343.5437.2834.6726.5512.560.260.12
Earnings Per Share-14.31-10.68-7.71-7.07-4.81-1.83-2.02-13.79-171.59
Operating Cash Flow-564-413-281-190-98.43-59.6943.45-21.04-12.22
Capital Expenditures-71.03-55.74-62.24-28.03-7.06-8.71-8.67-0.87-0.40
Free Cash Flow-635-469-343-218-105-68.4034.78-21.91-12.62
Cash & Equivalents1,1061,3851,29070451847420667.0129.32
Total Debt19115315512061.90----
Net Cash / Debt9151,2321,13558445647420667.0129.32
Assets1,7272,2431,9011,1181,00255722469.3230.92
Liabilities44235827724915265.4872.725.234.22
Book Value1,2851,8851,623869850491152-55.75-55.71
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bluebird Bio, Inc.
Country United States
Employees 1,167
CEO Nick Leschly

Stock Information

Ticker Symbol BLUE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BLUE
IPO Date June 19, 2013

Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.